Fierce Biotech
by Conor Hale
October 21, 2019
Drug discovery has always been a slow and laborious process by nature, with researchers finding dead ends much more frequently than successful routes to the clinic. The advent of AI promises to chart paths through that maze much faster, and it’s kicked off a gold rush of projects and collaborations as biopharma companies aim to reach their goals first.
One public-private partnership could help illuminate the way forward for others: The ATOM consortium, for Accelerating Therapeutics for Opportunities in Medicine, encompasses a suite of projects to hasten precompetitive drug discovery practices—with the objective of getting a potential drug from a target to patient testing in less than a year…
